Strictureplasty in Crohn’s Disease: Short and Long-Term Follow-Up

Introduction. The aim of this study is to evaluate the outcome of introduction of early surgery in the course of isolated ileocecal Crohn’s disease, where there is no absolute indication of surgery. Methods. Observational study involving patients with isolated ileocecal Crohn’s disease who underwent early surgical resection (within one year of the presentation of the hospital). A complete blood count, ESR, and CRP were done and compared between the preoperative value, 1st postoperative visit (3-4 weeks), and last follow-up visit. Statistical analysis was done using Analysis of Variance (ANOVA) to compare the different figures. Results. There was a statistically significant increase in the hemoglobin levels between preoperative, postoperative, and long-term follow-up and a significant decrease in leukocyte count between the pre- and postoperative values (F=19.8, p<0.001 and F=8.9, p=0.002, resp.). Similarly, the ESR and CRP values were decreased significantly at long-term follow-up (F=8.5, p=0.019 and F=8.3, p=0.013, resp.). Conclusion. Early surgical resection in isolated ileocaecal Crohn’s disease achieved significant biochemical improvements. These successful results in this small number of patients indicate that early surgical intervention may provide better outcomes. These initial results encourage larger and comparative studies of long-term results versus long-term use of biological agents.

Download Full-text

CS.2.2 ENDOSCOPIC PNEUMATIC DILATATION IN STENOSING CROHN'S DISEASE: LONG-TERM FOLLOW-UP

Digestive and Liver Disease ◽

10.1016/s1590-8658(10)60010-2 ◽

2010 ◽

Vol 42 ◽

pp. S64

Author(s):

S. Morini ◽

R. Lorenzetti ◽

C. Hassan ◽

A. Zullo ◽

S. Campo

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Pneumatic Dilatation ◽

Long Term Follow Up

Download Full-text

P405 Predictors of endoscopic recurrence in a long term follow up cohort of Crohn's disease patients – How effective is azathioprine? A single tertiary referral center experience

Journal of Crohn s and Colitis ◽

10.1016/s1873-9946(13)60426-2 ◽

2013 ◽

Vol 7 ◽

pp. S172

Author(s):

Y. Erzin ◽

G. Sisman ◽

I. Hatemi ◽

B. Baca ◽

I. Hamzaoglu ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Tertiary Referral ◽

Tertiary Referral Center ◽

Referral Center ◽

Endoscopic Recurrence ◽

Long Term Follow Up

Download Full-text

P451 Short-and long-term effectiveness of ustekinumab in patients with Crohn’s disease: real-world data from a German IBD cohort

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjz203.580 ◽

2020 ◽

Vol 14 (Supplement_1) ◽

pp. S405-S405

Author(s):

A Kubesch ◽

L Rueter ◽

K Farrag ◽

T Krause ◽

K Stienecker ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Real World ◽

Treatment Options ◽

Real World Data ◽

Free Response ◽

Faecal Calprotectin ◽

Short And Long Term

Abstract Background The IL-12/23 inhibitor ustekinumab (UST) opened up new treatment options for patients with Crohn’s disease (CD). Due to the recent approval, Real-World German data on long-term efficacy and safety are lacking. This study aimed to assess the clinical course of CD patients under UST therapy and to identify potential predictive markers. Methods Patients with CD receiving UST treatment in three hospitals and two outpatient centres were included and retrospectively analysed. Rates for short- and long-term remission and response were analysed with the help of clinical (Harvey–Bradshaw Index [HBI]) and biochemical (C-reactive protein [CRP], faecal calprotectin [fCal]) parameters for disease activity. Results Data from 180 patients were evaluated. One hundred six patients had a follow-up of at least 8 weeks and were included. 96.2% of the patients were pre-exposed to anti- TNFα agents and 34.4% to both anti-TNFα and anti-integrin. The median follow-up was 49.1 weeks (95% CI 42.03–56.25). At week 8, 51 patients (54.8%) showed response to UST, and 24 (24.7%) were in remission. At week 48, 39 (41.9%) responded to UST, and 20 patients (21.5%) were in remission. Steroid-free response and remission at week eight were achieved by 30.1%, and 19.3% of patients. At week 48, 26.9% showed steroid-free response to UST, and 15.1% of the initial patient population was in steroid-free remission. Clinical response at week 16 was independently associated with remission at week 48. Conclusion Our study confirms short- and long-term UST effectiveness and tolerability in a cohort of multi-treatment exposed patients.

Download Full-text